Management of Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) in an Elderly Patient with Cutaneous Involvement
Expert perspectives on the management of blastic plasmacytoid dendritic cell neoplasm (BPDCN) from a case-based peer discussion. The segments cover an overview of BPDCN, including clinical hallmarks and diagnostic challenges, as well as the appropriateness of initial therapy with tagraxofusp based on NCCN guidelines. The discussion explores the mechanism of action and potential efficacy of tagraxofusp, recent clinical trial data like the CADENZA study, and the potential of anti-CD123 CAR T-cell therapy for BPDCN. The segments also evaluate strategies for monitoring and mitigating adverse events, particularly capillary leak syndrome, quality of life considerations with various BPDCN treatments, and the future landscape with emerging research and limitations of current options, featuring insights from Dr. James K. McCloskey II.
